Elsevier

Leukemia Research

Volume 31, Issue 1, January 2007, Pages 27-32
Leukemia Research

Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene

https://doi.org/10.1016/j.leukres.2006.04.011Get rights and content

Abstract

Lipid kinase PIK3CA mutations have been described in several cancers. They clustered in two ‘hot spots’ located in helical (exon 9) and kinase (exon 20) domains associated with increased kinase activity strongly suggesting oncogenic potential. Mutational analysis of previously unexamined tumors showed an amino acid change from threonine to alanine (T1025A) in exon 20 in one of 28 endometrial cancer samples and 6 endometrial cell lines. Additionally, a silent polymorphism (T1025T) was found in two of 20 MDS samples, one of 43 NHL samples, two of 40 osteosarcoma samples and Ishikawa. The polymorphism was established by identifying two of 92 normal samples with the same change. No PIK3CA mutations were found in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and non-Hodgkin lymphomas (NHL) as well as in osteosarcomas, prostate and ovarian cancer samples. Additionally, a previously unidentified PIK3CA pseudogene spanning exons 9–13 on chromosome 22 was discovered.

Introduction

Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that is a known regulator of cellular growth and proliferation. The PI3K pathway plays a critical role in the development of cancer. Four different classes (I–IV) of the PI3K family are known in mammals [1], [2]. Initially, Samuels et al. [3] screened 16 members of the PI3K family for mutations in colorectal cancer. Class IA p110-alpha catalytic subunit (PIK3CA) was the only member that was found with somatic mutations [3]. Between 19% and 32% of colon cancers have PIK3CA mutations [3], [4]. Other tumors were also examined by several investigators for PIK3CA mutations in primary samples and cell lines including gastric (4–25% samples mutated) [3], [5], [6], breast (8–40%) [3], [4], [6], [7], lung (1–4%) [3], [6], ovary (6%) [4], liver (36%) [6], glioblastomas (5–27%) [3], [8], oligodendrogliomas (14%) [8], medulloblastomas (5%) [8], astrocytomas (3%) [8] and acute myeloid leukemia (AML) plus acute lymphoblastic leukemia (1%) [6]. The mutations clustered in two ‘hot spots’ located in the helical (exon 9) and kinase (exon 20) domains.

We performed mutational screening analysis of PIK3CA in several so far uninvestigated cancers including myelodysplastic syndromes (MDS), non-Hodgkin lymphomas (NHL), endometrial and prostate cancers, as well as AML and ovarian cancers. Cell lines and patient samples were examined by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and nucleotide sequencing of the two ‘hot spots’.

Section snippets

Cell lines

Human tumor cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA) (Table 1). Genomic DNA (gDNA) was extracted using phenol-chloroform and ethanol precipitation.

Patients

Samples were obtained from patients with endometrial cancer (28 samples), NHL (43 samples), MDS (20 samples), AML (26 samples), osteosarcoma (40 samples), prostate cancer (12 samples), ovarian cancer (18 samples) and normal peripheral blood of 92 individuals who underwent routine blood-drawing; all samples

Mutational analysis of eight colorectal cell lines as positive controls

The PIK3CA gene was analyzed for variation in the coding region in eight colorectal cancer cell lines, which were used as positive controls since PIK3CA mutations were previously identified in several of these cell lines (Table 1). We examined exons 9 and 20, since it was reported previously that >75% of the mutations found in a large number of cancers occurred in these regions. Variation in migration patterns was examined by SSCP analysis after PCR amplification. Abberantly shifted bands were

Discussion

Mutational analysis of a variety of human cancers discovered mutations in the PIK3CA gene, which encodes the catalytic subunit p110α of PI3-kinase [3], [4], [5], [6], [7], [8]. Functional significance of these mutations was suggested because: (i) they cluster in the critical exon 9 (helical domain) and exon 20 (kinase domain) regions; (ii) they are mostly nonsynonymous; (iii) highly conserved residues are primarily affected; (iv) mutant protein showed increased kinase activity [3]; and (v)

Acknowledgements

We thank Dr. Bert Vogelstein (Johns Hopkins University, Baltimore) for his helpful suggestions and sharing of reagents.

We thank the Inger Foundation, Parker Hughes Trust, The King Harbor Yacht Club Tom Collier Memorial Fund and an NIH grant. HPK is a member of the Jonsson Cancer Center, the Molecular Biology Institute of UCLA and has the endowed Mark Goodson Chair of Oncology Research at Cedars-Sinai Medical Center/UCLA School of Medicine. This work was moreover supported in part by a

References (10)

  • B. Vanhaesebroeck et al.

    Signaling by distinct classes of phosphoinositide 3-kinases

    Exp Cell Res

    (1999)
  • J. Paez et al.

    PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling

    Cancer Treat Res

    (2003)
  • Y. Samuels et al.

    High frequency of mutations of the PIK3CA gene in human cancers

    Science

    (2004)
  • I.G. Campbell et al.

    Mutation of the PIK3CA gene in ovarian and breast cancer

    Cancer Res

    (2004)
  • V.S. Li et al.

    Mutations of PIK3CA in gastric adenocarcinoma

    BMC Cancer

    (2005)
There are more references available in the full text version of this article.

Cited by (60)

  • Development of a multiplex allele-specific qPCR approach for testing PIK3CA mutations in patients with colorectal cancer

    2022, Heliyon
    Citation Excerpt :

    Using the criteria mentioned above, mutations R88Q [37], N345K [37], C420R [38], Q546K [3], M1043I [39], H1047Y [38] (Table 3) were tested in the present study, as they were previously identified in samples from patients with CRC. A mutation E545A [40], characterized as activating, was discarded from the present study, as it was detected in the PIK3CA pseudogene [41]. A set of plasmids was constructed based on the pBlueScript II SK (+) vector and 200 bp fragments of the PIK3CA gene as control samples for evaluating the multiplex qPCR efficiency.

  • The wnt/β-catenin pathway is deregulated in cemento-ossifying fibromas

    2018, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
    Citation Excerpt :

    Several mutations in PIK3 CA have been described in human neoplasms, predominantly in 2 hotspot regions in exons 9 and 20.25 Mutations in this gene were also reported in osteosarcoma26,27 and ameloblastoma.28 Another missense SNV was detected in the MET proto-oncogene, which is related to growth factor receptors.29

View all citing articles on Scopus
View full text